Description
The HOYA Vivinex iSert XY1 Monofocal Preloaded Intraocular Lens (IOL) is a sophisticated solution designed for cataract surgery, offering exceptional clarity and performance. Crafted from glistening-free hydrophobic acrylic, this lens includes both UV and blue light filters, ensuring comprehensive eye protection.
Optic Design
- Aspheric Optic: The proprietary aspheric design helps in compensating for corneal spherical aberration, enhancing visual outcomes.
- Edge Profile: Features a biconvex profile with a square, thin, and textured optic edge to reduce posterior capsule opacification (PCO).
Haptic Design
- Surface Texture: The textured-rough haptic surface improves lens stability and minimizes adhesion.
- Active Oxygen Processing: Provides a smooth surface with a square posterior optic edge to further minimize PCO.
Dimensions
- Optic Diameter: 6.00 mm
- Overall Length: 13.00 mm
- Power Range: Available from +6.00 D to +30.00 D in 0.50 D increments.
Optical Constants
- Nominal A-Constant: 118.9, with customization recommended for precise outcomes.
- Optimized Constants: Includes parameters for Haigis, Hoffer Q, Holladay 1, and SRK/T formulas.
Injector System
Preloaded in the Vivinex iSert® or multiSert™ injector system, the lens allows for a recommended incision size of 2.20 mm. The system supports single-handed or two-handed injection, providing flexibility and precision during implantation.
Clinical Performance
- Clarity: Demonstrates glistening-free clarity with a low incidence of PCO.
- Durability: No evidence of stress fractures or material damage post-implantation.
- Predictability: Offers high refractive predictability and enhances intermediate vision.
Professional Use
This product is intended for use by healthcare professionals, with detailed instructions provided for implantation. For comprehensive indications and contraindications, refer to the Instructions For Use.
HOYA's commitment to innovation and quality is evident in the Vivinex iSert XY1, making it a reliable choice for enhancing visual outcomes in cataract patients.
